We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
vernie
ramalingam
vernie.ramalingam@nhs.net
Andrew
Williamson
a.williamson@kinomica.com
Dr
Debashis
Sarker
debashis.sarker@kcl.ac.uk
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Primary liver cancer is the fourth most prevalent cancer worldwide and is predicted to cause 1 million deaths by 2030 [WHO/UN data]. Hepatocellular Carcinoma (HCC) accounts for 90% of all liver cancer cases with around 5,900 new cases in the UK every year, and incidence is projected to rise by 38% by 2035 [CRUK]. Overall survival remains poor at < 20% at 5 years. However, systemic therapy options for these patients is increasing, and includes immunotherapies as well as targeted therapies. Consequently, all HCC patients are currently required to have baseline biopsies taken, as part of standard clinical care, prior to starting systemic therapies, with the intention of providing individualised care where possible.
The aim of the proposed work is to extract the biological signature (phosphoproteomics) of a given patient's cancer from tumour tissue that is obtained during standard of care surgery or biopsy procedures. This data will then be computationally modelled to develop an algorithm to identify features in the biological signature that can be used to predict whether the patient will respond to one therapy over another.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Clinical Laboratory Study;
You can take part if:
You may not be able to take part if:
1. No Liver Biobank Consent 2. No tumor biopsy 3. Insufficient biopsy sample 4. < 50% tumor in biopsy sample 5. Paediatric age group < 18 years
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Debashis
Sarker
debashis.sarker@kcl.ac.uk
vernie
ramalingam
vernie.ramalingam@nhs.net
Andrew
Williamson
a.williamson@kinomica.com
The study is sponsored by KINOMICA LIMITED and funded by Innovate UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 53986
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
